Valuation: XORTX Therapeutics Inc.

Market Cap 1.82M 1.3M 1.17M 1.07M 972K 124M 1.85M 12.79M 5.13M 65.03M 4.89M 4.78M 205M P/E 2024
-0.98x
P/E 2025 -1x
Enterprise Value 989K 709K 635K 584K 529K 67.33M 1.01M 6.97M 2.8M 35.42M 2.66M 2.6M 112M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
98.47%
Yield 2024 *
-
Yield 2025 -
1 day-2.91%
1 week+8.68%
Current month-40.83%
1 month-40.83%
3 months-50.50%
6 months-65.03%
Current year-64.41%
1 week 0.83
Extreme 0.83
1.15
1 month 0.83
Extreme 0.83
2.08
Current year 0.83
Extreme 0.83
3.6
1 year 0.83
Extreme 0.83
3.6
3 years 0.83
Extreme 0.83
35
5 years 0.83
Extreme 0.83
265.05
10 years 0.83
Extreme 0.83
368.33
Manager TitleAgeSince
Chief Executive Officer 28 15/06/2026
Chief Executive Officer 66 09/01/2018
Director of Finance/CFO 62 19/12/2024
Director TitleAgeSince
Director/Board Member 66 09/01/2018
Director/Board Member 50 24/03/2026
Director/Board Member - 24/03/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%+8.68%-68.20%-92.46% 1.82M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.01%+7.65%+36.25%+176.44% 39.43B
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%

Financials

2024 2025
Net sales - -
Net income -3.31M -2.37M -2.13M -1.96M -1.77M -225M -3.38M -23.33M -9.37M -119M -8.91M -8.72M -374M -2.66M -1.9M -1.71M -1.57M -1.42M -181M -2.71M -18.7M -7.51M -95.09M -7.14M -6.99M -300M
Net Debt -2.43M -1.75M -1.56M -1.44M -1.3M -166M -2.48M -17.14M -6.88M -87.16M -6.55M -6.41M -275M -827K -593K -531K -488K -443K -56.29M -843K -5.82M -2.34M -29.61M -2.23M -2.18M -93.39M
Projected Income Statement - Annual - XORTX Therapeutics Inc.
Logo XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Employees
-
Date Price Change Volume
30/10/26 $1.000 -2.91% 24,986
29/10/26 $1.030 -1.90% 14,321
28/10/26 $1.050 -4.55% 11,055
27/10/26 $1.100 +3.77% 39,168
26/10/26 $1.060 +15.20% 120,713

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - XORTX Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. XRTX Stock